D.I. TRUKHAN¹, A.L. MAZUROV²

¹Omsk State Medical University, 12 Lenin Str., Omsk, Russian Federation, 644099

²Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetskiy, 1 Partizan Zheleznyak Str., Krasnoyarsk, Russian Federation, 660022 

Trukhan D.I. — D. Med. Sc., Associate Professor, Professor of the Department of Internal Diseases and Polyclinic Therapy, e-mail: dmitry_trukhan@mail.ru

Davydov E.L. — D. Med. Sc., Associate Professor, Associate Professor of the Department of Propaedeutics of Internal Diseases and Therapy, professor of the Chair of internal medicine and therapy, e-mail: devgenii@bk.ru

 The article deals with the issues of prevention of stroke and cognitive impairment in hypertensive patients at the stage of primary health care. The data of the study Syst-Eur (The Systolic Hypertension in Europe) clearly demonstrate the effectiveness of the dihydropyridine calcium antagonist nitrendipine in reducing the risk of stroke, cognitive impairment and dementia in patients with hypertension. The emergence of the drug nitrendipine — Nitremed® — in the Russian pharmaceutical market makes it possible to optimize the prevention of cerebrovascular disease and cognitive impairment in hypertensive patients.

Key words: primary health care, hypertension, stroke, light and moderate cognitive impairment, dementia, prevention, nitrendipine, Nitremed®.